4.6 Article

Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice

Journal

BIOMEDICAL JOURNAL
Volume 44, Issue 6, Pages S210-S217

Publisher

ELSEVIER
DOI: 10.1016/j.bj.2020.10.002

Keywords

Type 1 diabetes; Islets transplantation; Dipeptidyl peptidase-IV inhibitors

Ask authors/readers for more resources

The study found that the DPP-IV inhibitor LAF237 can improve glucose tolerance and increase graft beta-cell mass in diabetic mice transplanted with a sufficient number of islets. This suggests that the effects of DPP-IV inhibitors are influenced by the implanted islet mass.
Background: Previous studies showed inconsistent Results of the effects of dipeptidyl peptidase (DPP)-IV inhibitors on syngeneic mouse islet transplantation. We hypothesized that the implanted islet numbers are critical for the effects of DPP-IV inhibitors on the outcomes of transplantation. Methods: One hundred and fifty or three hundred islets were syngeneically transplanted under the renal capsule of each streptozocin-diabetic C57BL/6 mouse and recipients were then treated without or with LAF237 (10 mg/kg/day, po) for 6 weeks. After transplantation, recipients' blood glucose, body weight and intraperitoneal glucose tolerance test (IPGTT) were followed-up periodically. The graft was removed for the measurement of beta-cell mass at 6 weeks. Results: In recipients with 150 islets, it was not significantly different between the LAF237-treated group (n = 14) and control group (n = 14) in terms of the blood glucose, body weight, glucose tolerance at 2, 4 and 6 weeks or the graft beta-cell mass at 6 weeks. In contrast, in recipients with 300 islets, the LAF237-treated group (n = 24) did have a lower area under the curve of the IPGTT at 4 weeks (p = 0.0237) and 6 weeks (p = 0.0113) as well as more graft bcell mass at 6 weeks (0.655 +/- 0.008 mg vs. 0.435 +/- 0.006 mg, p = 0.0463) than controls (n = 24). Conclusions: Our findings revealed 6-week treatment of LAF237 improves glucose tolerance and increases graft beta-cell mass in diabetic mice transplanted with a sufficient number but not a marginal number of islets. These indicate that the effects of DPP-IV inhibitors are influenced by the implanted islet mass.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available